Contrast

Contact

Share

MyChart

Help

Yale New Haven Health’s Lisa Stump named as one of 18 women leaders selected for Carol Emmott Fellowship

Thursday, December 7, 2017

New Haven, CT (Dec. 7, 2017) – Lisa Stump, senior vice president and chief information officer for Yale New Haven Health and Yale School of Medicine, has been selected as one of 18 to receive a Carol Emmott Fellowship. She will be part of a one-of-a-kind program for professionals who have demonstrated potential to ascend to senior executive and board-level roles.

The 14-month program expands the leadership capacity of the fellows, who are chosen for their ability to deliver results within their organizations and potential to advance to senior executive roles in health.

Stump joined YNHH in 1996 and has held a number of roles of increased responsibility, including director of Pharmacy, administrative director in clinical informatics and vice president, Epic Project. Before becoming CIO, she was associate chief information officer, leading integration of Information Technology Services staff across YNHHS. She has also led consolidation of multiple technology platforms in bed management, infection control, laboratory information and blood bank; spearheaded the pilot and launch of the InSight Tele-ICU platform; and launched several innovation partnerships with technology and applications vendors. She holds a faculty appointment at Sacred Heart University in clinical informatics. Stump earned her BS in pharmacy from the University of Connecticut and her MS in pharmacy from The Ohio State University.

The fellowship is tailored to expand the connections and experiences that top leadership candidates require to have the most influence in improving health for all. Fellows are nominated by their sponsoring organization and compete for acceptance into the program with a proposed impact project that transcends their current role to advance an area of health. They continue to work for their organizations during the fellowship, which provides them with more opportunities to build networking relationships with other top leaders as well as exercise high-level skills as they implement their impact projects.

The newly selected class represents an expansion of the program, growing from 15 to 18 fellows and from 12 sponsoring organizations to 15. The class of 2018 also reflects a broader range of disciplines from emergency medicine and surgery to healthcare information technology and finance.

Yale New Haven Health (YNHHS), the largest and most comprehensive healthcare system in Connecticut, is recognized for advanced clinical care, quality, service, cost effectiveness and commitment to improving the health status of the communities it serves. YNHHS includes five hospitals – Bridgeport, Greenwich, Lawrence + Memorial, Westerly and Yale New Haven hospitals, several specialty networks and Northeast Medical Group, a non-profit medical foundation with several hundred community-based and hospital-employed physicians. YNHHS is affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale New Haven Hospital is the primary teaching hospital of Yale School of Medicine. www.ynhhs.org

Similar Articles

9/15/2021

Marna Borgstrom to retire in 2022 as CEO of Yale New Haven Health

New Haven, CT (Sept. 15, 2021) – After more than 43 years of exceptional service, Marna P. Borgstom has announced her intent to retire as chief executive officer of Yale New Haven Health. Her retirement is effective on March 25 2022.

9/15/2021

Christopher O’Connor to become CEO of Yale New Haven Health

New Haven, CT (Sept. 15, 2021) – Christopher O’Connor has been named the CEO of Yale New Haven Health (YNHHS), effective March 25, 2022 when current CEO Marna P. Borgstrom retires, announced Vince Calarco, Chair of the YNHHS Board of Trustees. O’Connor currently serves as president of the Health System having been named to that position in August of 2020.

9/1/2021

Outpatient Monoclonal Antibody Treatment decreases hospitalization risk in COVID-19 patients

New Haven, CT (September 1, 2021) – While not a new treatment, monoclonal antibody therapy is being administered more regularly and effectively to patients with mild to moderate COVID-19 with excellent results.